1. CYP11A1 and CYP17 promoter polymorphisms associate with hyperandrogenemia in polycystic ovary syndrome 
Madhavi Pusalkar, M.Sc., Pervin Meherji, M.D., Ph.D., Jyotsna Gokral, M.B., B.S., D.G.O, Saravanan Chinnaraj, B.Sc., Anurupa Maitra, Ph.D 
Fertility and Sterility 
Volume 92, Issue 2, Pages (August 2009)
DOI: /j.fertnstert
Copyright © 2009 American Society for Reproductive Medicine Terms and Conditions

2. Figure 1
Comparison of T levels with polymorphisms in CYP11A1 and CYP17 genes, in control subjects and subjects with PCOS. Bars with similar superscripts are statistically significantly different. (a): Comparison of CYP11A1 polymorphic 6R groups and nonpolymorphic 4R groups in control subjects and subjects with PCOS (a: P=.008, b: P<.0001, c: P<.0001). In subjects with PCOS, the hormone levels in the polymorphic 6R group was significantly elevated compared with the nonpolymorphic 4R group. A similar comparison in controls did not show any significant differences.(b): Comparison of T levels in individuals with wild-type T genotype and polymorphic C genotype in control subjects and subjects with PCOS (a, b, c: P<.0001). In subjects with PCOS, the hormone levels in the polymorphic C group were significantly elevated compared with the nonpolymorphic T group in subjects with PCOS. A similar comparison in controls did not show any significant differences.(c): Combined effect of polymorphisms in CYP11A1 and CYP17 on T levels in control subjects (a: P<.01).(d): Combined effect of polymorphisms in CYP11A1 and CYP17 on T levels in subjects with PCOS (a, b: P<.05; c, d: P<.01; e: P<.0001). An additive effect on T levels was seen in the subjects with PCOS.
Fertility and Sterility  , DOI: ( /j.fertnstert )
Copyright © 2009 American Society for Reproductive Medicine Terms and Conditions